New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
09:03 EDTDCTH, ATRSAntares Pharma announces resignation of CEO Wotton, names Hobbs as CEO
Antares Pharma (ATRS) announced the resignation of Paul K. Wotton, Ph.D. who informed the companys Board of Directors that he will assume the position of CEO of a development stage biotechnology company. Wotton also has resigned from the Antares Board of Directors. Antares Pharma also announced today the appointment of Eamonn P. Hobbs to the position of President and CEO of the company effective immediately. Hobbs joined the Antares Board of Directors in August 2009 and has over 30 years of experience in the pharmaceutical, medical device, and combination products industry, including the medical specialty fields of radiology, vascular surgery, interventional cardiology, oncology and gastroenterology. Hobbs was previously the President and CEO of Delcath Systems (DCTH).
News For ATRS;DCTH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
10:32 EDTATRSAntares Pharma management to meet with Guggenheim
Subscribe for More Information
07:02 EDTATRSAntares Pharma names James Fickenscher as SVP, CFO
Subscribe for More Information
November 14, 2014
07:14 EDTATRSAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 10, 2014
06:40 EDTDCTHDelcath Systems treats first patient in Melphalan/HDS Phase 2 trial
Delcath Systems announced that the first treatment has been performed in the company's Global Phase 2 Clinical Program for first-line treatment of patients with unresectable hepatocellular carcinoma, or HCC, or primary liver cancer. A team led by Prof. Dr. med. Thomas J. Vogl, Director of the Institute for Diagnostic and Interventional Radiology at Goethe University Hospital Frankfurt, Germany, treated its first case on November 5. The treating physicians reported that the patient was treated successfully. In Europe, the Company's Phase 2 trial program will investigate the safety and efficacy of Melphalan/HDS treatment without sorafenib in patients with unresectable liver cancer confined to the liver, evaluate tumor response as measured by modified Response Evaluation Criteria in Solid Tumor, or mRECIST, and assess progression-free survival and safety. Additional analyses will be conducted to characterize the systemic exposure of melphalan administered by Melphalan/HDS, as well as assess patient-reported clinical outcomes, or quality-of-life. The Company's Phase 2 trial program is expected to include four to seven centers in Europe and the United States, and will seek to enroll approximately 30 patients.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use